Doctors Revision

Antimalarial Agents: ACTs, Artesunate, Quinine, Primaquine and Prevention

Text size
On this page

Overview

The parasite life-cycle as a drug target

Antimalarials are classified by which stage of the Plasmodium life-cycle they kill:

  • Tissue (exo-erythrocytic) schizonticides — kill liver-stage hypnozoites of P. vivax/P. ovale; example: primaquine. This is "radical cure" (prevents relapse).
  • Blood (erythrocytic) schizonticides — kill the asexual red-cell stages that cause symptoms and severe disease; examples: artemisinins, quinine, chloroquine, lumefantrine, SP. This is what "treatment" means day-to-day.
  • Gametocytocides — kill sexual stages that infect mosquitoes; example: primaquine (single low dose with ACT), artemisinins partially.
  • Sporonticides / transmission-blocking — prevent mosquito-stage development; SP and primaquine contribute.
  • Causal (true) prophylaxis — prevent liver-stage establishment in non-immune travellers; examples: atovaquone-proguanil, doxycycline (not routinely used in endemic Uganda).

P. falciparum — the dominant species in Uganda — has no persistent liver hypnozoite stage, so radical cure is not needed; treatment targets blood stages only. P. vivax and P. ovale can hide in the liver and relapse months later, which is why a primaquine "anti-relapse" course exists.

Classification by mechanism

Scroll the table sideways on a smaller screen.

The main antimalarial classes
Class / drugsMechanism of actionStage targetedKey point
Artemisinins: artemether, artesunate, dihydroartemisininActivated by haem-iron inside the parasite → free radicals that alkylate and damage parasite proteins/membranesAll asexual blood stages; early gametocytesFastest parasite killers known (clear parasitaemia in hours); short half-life → never used as monotherapy
Aryl amino alcohols / quinolines: quinine, lumefantrine, mefloquine, chloroquine (4-aminoquinoline)Accumulate in the acidic food vacuole → inhibit haem detoxification (haem polymerisation to haemozoin), poisoning the parasite with its own haemAsexual blood schizonts (mainly)Longer half-lives "mop up" after artemisinins; chloroquine resistance is widespread in P. falciparum in East Africa
Antifolates: sulfadoxine-pyrimethamine (SP), proguanil, dapsoneInhibit dihydropteroate synthase (sulfadoxine) and dihydrofolate reductase (pyrimethamine) sequentially → block folate and DNA synthesisAsexual blood schizontsNow reserved for IPTp in pregnancy and intermittent preventive therapy in infants (resistance prevents first-line curative use)
8-Aminoquinolines: primaquine, tafenoquineOxidative stress to parasite mitochondria; exact mechanism still debatedLiver hypnozoites (radical cure) + gametocytesCauses haemolysis in G6PD deficiency — test before the 14-day anti-relapse course; the single transmission-blocking dose needs no test
Naphthoquinone: atovaquone (+ proguanil)Inhibits mitochondrial electron transport at cytochrome bc1Hepatic and blood stages (causal + suppressive)Traveller prophylaxis and second-line therapy; take with food (fat ↑ absorption)
Antibiotics with antimalarial activity: doxycycline, clindamycinInhibit parasite protein synthesis (apoplast)Asexual blood schizonts (slow)Only in combination (e.g. quinine + doxycycline second line)

Artemether-lumefantrine and other ACTs

Figure 1: Malaria treatment algorithm for Uganda showing confirmation by RDT or microscopy, artemether-lumefantrine weight bands for uncomplicated malaria, IV artesunate schedule for severe malaria, combination therapy rationale, and prevention with IPTp and primaquine
Figure 1: The malaria treatment algorithm at a glance.

Artemisinin-based combination therapy (ACT) pairs a fast, short-lived artemisinin derivative with a slower, longer-lived partner drug. The artemisinin component drops the parasite biomass by ~10,000-fold in the first 3 days; the partner drug clears the survivors. Artemisinin monotherapy is banned because sub-curative exposure selects partial resistance (delayed parasite clearance has emerged in the Greater Mekong region and is being watched closely in Africa).

Scroll the table sideways on a smaller screen.

Artemether-lumefantrine (Coartem®) 20/120 mg — the first-line ACT in Uganda
ItemDetails
CompositionArtemether 20 mg + lumefantrine 120 mg per tablet (fixed-dose combination, dispersible paediatric formulation available)
Dose (weight bands)5–14 kg: 1 tablet per dose ・ 15–24 kg: 2 tablets ・ 25–34 kg: 3 tablets ・ >34 kg (adult): 4 tablets per dose
ScheduleTwice daily for 3 days (6 doses); day-1 dose 2 is given 8–12 hours after dose 1, then morning/evening on days 2 and 3
AdministrationTake with fat-containing food or milk (lumefantrine absorption is fat-dependent — a starving patient under-doses); repeat the dose if vomiting occurs within 30 minutes
Adverse effectsGenerally well tolerated: headache, dizziness, anorexia, GI upset, transient QT prolongation; hypersensitivity rare
Contraindications / cautionsHypersensitivity to components; caution with known QT prolongation or on other QT drugs (amiodarone, some antipsychotics); avoid in first-trimester pregnancy unless alternatives unavailable (national policy per current guidance); weak CYP3A4 interactions (rifampicin reduces levels; avoid St John's wort)
CounsellingComplete all 6 doses even when fever resolves; take with food; return if fever returns within 14 days (possible resistance, adherence failure, or wrong diagnosis)

Second-line ACTs and alternatives: Artesunate-amodiaquine (2nd line in Uganda; same artemisinin principles, amodiaquine is the partner) and quinine + doxycycline or clindamycin (7 days) for treatment failures and where ACT is contraindicated — doxycycline is not for children under 8 years or pregnant women (use clindamycin instead).

Severe malaria: IV artesunate

Severe P. falciparum malaria is a medical emergency with high mortality — impaired consciousness, repeated convulsions, prostration, acidotic breathing, severe anaemia, hypoglycaemia, renal impairment, jaundice, shock, or hyperparasitaemia. Do not wait for confirmation to treat suspected severe malaria — give the first dose immediately.

Scroll the table sideways on a smaller screen.

Injectable artesunate — the drug of choice for severe malaria (WHO)
ItemDetails
Dose2.4 mg/kg IV (3 mg/kg if <20 kg) at 0, 12 and 24 hours, then once daily; minimum of 3 doses / 24 hours parenteral and until the patient can take oral medication
RouteIV (dilute in 5% dextrose); may be given IM into the anterior thigh if no IV access — absorption is reliable
Follow-onOnce the patient tolerates oral intake: complete a full 3-day ACT course (parenteral artesunate alone does not give partner-drug cover — parasite recrudescence follows)
Adverse effectsRemarkably safe; transient neutropenia, delayed haemolysis ~1–3 weeks after treatment (monitor Hb at follow-up in severe cases), injection-site pain IM
AlternativesIM artemether, or quinine (IV loading 20 mg/kg then 10 mg/kg 8-hourly with ECG monitoring where possible) where artesunate is unavailable — inferior and more toxic (hypoglycaemia, cinchonism)
AdjunctsMonitor and treat hypoglycaemia, acidosis, seizures (rectal diazepam/lorazepam), anaemia (transfusion per criteria), renal failure; no steroids, no heparin

Quinine, chloroquine, SP and primaquine

Scroll the table sideways on a smaller screen.

The supporting cast — indications, doses, cautions
DrugDoseCurrent roleAdverse effects & cautions
Quinine (+ doxycycline/clindamycin)Treatment: 10 mg/kg salt (600 mg adult) 8-hourly oral × 3/7 days in combination; severe: IV as aboveSecond-line for ACT failure; severe malaria where artesunate unavailableCinchonism (tinnitus, deafness, headache, nausea), hypoglycaemia (dangerous in pregnancy — monitor), QT prolongation; doxycycline not in pregnancy/<8 y
Chloroquine25 mg base/kg total over 3 days (10, 10, 5 mg/kg)P. vivax/P. ovale blood stages (still usually sensitive); some countries use for P. falciparum where fully sensitivePruritus (common, esp. in dark skin), GI upset, headache, retinopathy and cardiotoxicity only with chronic use; NOT reliable against Ugandan falciparum
Sulfadoxine-pyrimethamine (SP)3 tablets (1500/75 mg) single dose; IPTp: at least 3 doses of 3 tablets from 2nd trimester, ≥1 month apart under direct observationIPTp in pregnancy; IPTi in infants where policy applies; occasional combination therapy partnerHypersensitivity (sulfa), GI upset; widespread falciparum resistance for curative use; avoid in late 3rd trimester sulfa allergy context per local guidance; give with folate caution discussions per ANC protocol
PrimaquineTransmission-blocking single dose: 0.75 mg base/kg (max 45 mg) with ACT — no G6PD test needed. Anti-relapse (vivax/ovale): 0.5 mg/kg daily × 14 days — test G6PD firstGametocyte clearance to interrupt transmission; radical cure of liver hypnozoitesHaemolysis in G6PD deficiency (test before 14-day course); methaemoglobinaemia; avoid in pregnancy (fetal G6PD status unknown)
Artesunate-amodiaquineWeight-banded FDC tablets once daily × 3 days (per national protocol)Second-line ACT in UgandaAs ACT class; amodiaquine partner adds agranulocytosis/hepatotoxicity risk in repeated courses

Chemoprevention and vector control

  • Insecticide-treated nets (ITNs) — the backbone of prevention: sleep under an ITN every night; re-treat/replace per programme; the single most cost-effective child-survival intervention.
  • IPTp-SP — ≥3 doses of SP from the second trimester, at least a month apart, under directly observed therapy; reduces low birth weight, maternal anaemia and neonatal mortality even in areas of partial SP resistance.
  • Seasonal malaria chemoprevention (SMC) — monthly amodiaquine + SP courses for children 3–59 months in defined high-transmission seasons (applied in parts of the Sahel; per national policy where introduced).
  • Intermittent preventive treatment in infants (IPTi) — SP alongside EPI vaccinations where policy applies.
  • Indoor residual spraying (IRS) and larval source management — public-health programme measures.
  • Traveller prophylaxis (non-immune visitors): atovaquone-proguanil daily starting 1–2 days before, during, and 7 days after travel; alternatives doxycycline (daily, 4 weeks after) or mefloquine (weekly) — rarely relevant for residents of endemic Uganda.

Choosing a regimen in Uganda

Scroll the table sideways on a smaller screen.

Situation → regimen (per Uganda Malaria Control Programme / UCG 2023 approach)
SituationRegimenKey checks
Uncomplicated P. falciparum (RDT/microscopy positive)Artemether-lumefantrine × 3 days by weight bandParasitological confirmation first (in any febrile patient, test before treating); dose with food; assess for danger signs
Treatment failure / ACT contraindicatedArtesunate-amodiaquine (2nd-line ACT) or quinine + doxycycline/clindamycin × 7 daysExclude non-adherence and vomiting before declaring failure; doxycycline if ≥8 y and not pregnant
Severe malaria (any species)IV/IM artesunate 2.4 mg/kg (3 mg/kg if <20 kg) at 0/12/24 h then daily + supportive care; complete oral ACT afterTreat immediately without waiting for confirmation; check glucose, Hb; manage seizures, acidosis, fluids carefully
P. vivax/P. ovale malariaChloroquine or ACT for blood stages + primaquine 0.5 mg/kg daily × 14 days (G6PD-tested)Ask about travel/relocation history; exclude pregnancy before primaquine
Pregnancy — uncomplicatedACT in 2nd and 3rd trimester per current WHO/national guidance (quinine + clindamycin 1st trimester)IPTp-SP at ANC; severe malaria in any trimester → artesunate (life-saving; benefit outweighs risk)
ProphylaxisITN + IPTp-SP in pregnancy; SMC/IPTi per national programmeANC documentation of SP doses; net usage counselling

Clinical scenarios

Scenario 1 — The unconscious child on arrival

A 4-year-old (16 kg) is brought in deeply unconscious (Blantyre coma score 2) with fever and a positive RDT. You recognise severe malaria with cerebral involvement and immediately give IV artesunate 3 mg/kg = 48 mg at 0, 12 and 24 hours then daily (children <20 kg get 3 mg/kg), plus a bedside blood glucose of 1.8 mmol/L → IV dextrose (hypoglycaemia is both a feature of severe malaria and a quinine/artesunate-adjacent danger). You check Hb (5.8 g/dL — severe anaemia → transfuse per criteria), control the temperature, and monitor breathing for acidosis. He wakes on day 2, takes oral fluids, and you complete a full 3-day AL course after the last parenteral dose. No steroids, no fluid boluses beyond correction of shock.

Scenario 2 — Dosing AL on the paediatric ward

A 10-kg toddler has uncomplicated malaria confirmed by RDT. Weight band 5–14 kg → 1 tablet of artemether-lumefantrine per dose, twice daily for 3 days (6 doses total), with the second day-1 dose 8–12 hours after the first. The mother says the child "hates food when febrile" — you explain that even milk or a small fatty snack with each dose markedly improves lumefantrine absorption, and that if he vomits within half an hour the dose should be repeated. You counsel her to return if fever returns within 14 days or he develops danger signs, and you do not add antibiotics — the cough is from the malaria itself.

Scenario 3 — The pregnant woman at ANC

A 26-year-old at 20 weeks' gestation attends ANC. She had malaria last month and worries about "those strong tablets harming the baby." You reassure her that in the 2nd and 3rd trimester, ACT is the recommended treatment and that untreated malaria is far more dangerous to the fetus than the drug. You check her ANC card: only one IPTp-SP dose so far — you give her the 2nd dose of 3 SP tablets under observation and schedule a 3rd at ≥1-month intervals, reinforce sleeping under an ITN nightly, and remind her that if she develops fever she must attend immediately for testing — quinine + clindamycin remains the option if treatment is needed in the first trimester.

Key points

References

  • WHO Guidelines for Malaria (updated recommendations), including the severe malaria artesunate guidance (Library reference.)
  • Uganda Malaria Control Programme treatment policy; Uganda Clinical Guidelines 2023 (Library reference.)
  • WHO policy brief: single-dose primaquine as a gametocytocide in P. falciparum malaria (Library reference.)
  • Katzung's Basic & Clinical Pharmacology — chemotherapy of malaria chapter (Library reference.)
  • Goodman & Gilman's The Pharmacological Basis of Therapeutics (Library reference.)
  • WHO Model List of Essential Medicines: antimalarial agents (Library reference.)

Further reading

For deeper study, compare this lesson with current guidance and standard references from recognised medical and pharmaceutical organisations.

For education only. Malaria regimens follow the Uganda Malaria Control Programme and Uganda Clinical Guidelines — always verify against current national policy in practice.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top